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AbstrAct
In septic patients, the onset of septic shock occurs due to the over-activation of 
monocytes. We tested the therapeutic potential of directly targeting innate immune 
cell activation to limit the cytokine storm and downstream phases. We initially 
investigated whether caspase-8 could be an appropriate target given it has recently 
been shown to be involved in microglial activation. We found that LPS caused a mild 
increase in caspase-8 activity and that the caspase-8 inhibitor IETD-fmk partially 
decreased monocyte activation. Furthermore, caspase-8 inhibition induced necroptotic 
cell death of activated monocytes. Despite inducing necroptosis, caspase-8 inhibition 
reduced LPS-induced expression and release of IL-1β and IL-10. Thus, blocking 
monocyte activation has positive effects on both the pro and anti-inflammatory 
phases of septic shock. We also found that in primary mouse monocytes, caspase-8 
inhibition did not reduce LPS-induced activation or induce necroptosis. On the other 
hand, broad caspase inhibitors, which have already been shown to improve survival 
in mouse models of sepsis, achieved both. Thus, given that monocyte activation can 
be regulated in humans via the inhibition of a single caspase, we propose that the 
therapeutic use of caspase-8 inhibitors could represent a more selective alternative 
that blocks both phases of septic shock at the source.
IntroductIon
Historically, sepsis represented one of the major 
causes of death until the discovery of antibiotics in the 
early 20th century. However, emerging diseases such as 
Ebola, H5N1 avian influenza or SARS, together with an 
increase in antibiotic resistance in previously controllable 
pathogens such as Mycobacterium tuberculosis or MRSA 
have led to sepsis once again becoming a global burden 
[1, 2]. This is due to the high mortality rates associated 
to severe sepsis, ranging from 20% to 80% in the event 
of a systemic inflammatory response syndrome (SIRS) 
[3]. Although SIRS has generally been associated with 
sepsis, it can also occur in non-infectious conditions 
such as trauma, burns or severe injuries. This is due to 
the fact that SIRS is initiated not only by the detection 
of pathogen-associated molecular patterns (PAMPs) but 
also damage-associated molecular patterns (DAMPs) [4, 
5]. The recognition of these molecules by monocytes 
and neutrophils in the bloodstream leads to uncontrolled 
activation, proliferation and the release of cytokines [6-
8]. The resultant cytokine cascade triggers an initial pro-
inflammatory state that leads to generalized inflammation 
and multi-organ failure. This inflammatory state also 
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causes lymphocyte and dendritic cell apoptosis, and 
deterioration of phagocyte function. The combined 
depletion and impaired activation of immune cells 
ultimately leads to an immunosuppressive state, which has 
been hypothesized to cause both the high mortality and the 
long-term side effects of sepsis [9, 10]. Furthermore, given 
the positive feedback nature of the resultant response, the 
irreversible cytokine storm can continue even after the 
clearance of any pathogen, complicating the treatment and 
thus worsening the prognosis [4, 11]. 
To date, there are no drugs specifically approved 
for the treatment of SIRS in humans. Clinical trials have 
mostly been based around decreasing the pro-inflammatory 
response by developing strategies to neutralize cytokines 
such as neutralizing antibodies or thrombogenic products. 
These strategies however cannot prevent the onset of the 
immunosuppressive state, and so current research is also 
focusing on apoptosis inhibitors to prevent lymphocyte 
and dendritic cell depletion [12-15]. Given that monocytes 
are the upstream cells in the process, as well as important 
modulators of the innate immune response, the regulation 
of monocyte activation could represent an alternative in 
the treatment and prevention of SIRS [16].
We therefore sought to further understand the 
mechanism of activation of blood monocytes. Previous 
studies have shown that multiple members of the 
caspase family of proteins are involved in regulating this 
process. Caspases, or cysteine-aspartic proteases, are 
most well known for their roles in apoptotic cell death 
[17]. However, it is becoming clear that they exhibit 
additional non-apoptotic roles, especially in cells of 
the myeloid lineage. For instance, caspase-8 has been 
shown to be critical for the differentiation of monocytes 
into macrophages [18-20]. Furthermore, it has been 
demonstrated that caspases 8, 3 and 7 play an important 
role in the neurotoxic pro-inflammatory activation of 
microglia [21, 22]. In line with this, caspase-8 inhibition 
led to decreased microglial activation and neuronal 
damage associated to inflammation. Finally, caspase-8 
has been shown to inhibit a type of cell death termed 
‘programmed necrosis’ or necroptosis by cleaving 
receptor-interacting protein kinase 1 (RIPK1) [23-25]. 
Necroptosis, or programmed necrosis, occurs downstream 
of RIPK1 activation, via oligomerization with receptor-
interacting protein kinase 3 (RIPK3) and subsequent 
activation of mixed lineage kinase domain-like protein 
(MLKL), which drives membrane disruption [26]. Since 
necroptotic cell death leads to the release of DAMPs from 
cells, the role of caspase-8 in inhibiting this process may 
also be important in controlling the activation of innate 
immune cells [27].
Here, we aimed to understand the role of caspase-8 
as a regulator of monocyte activation and its potential as 
a target for the control of SIRS. We found that caspase-8 
regulates human monocyte activation and caspase-8 
inhibition results in decreased monocyte activation and 
cytokine release. Furthermore, we also observed that 
caspase-8 inhibition of activating monocytes promotes 
their death by necroptosis, which could potentially reverse 
the accumulation of monocytes observed in SIRS. Similar 
results were achieved in mouse monocytes treated with 
broad caspase inhibitors, which have previously shown 
promise in murine models of septic shock. Together, these 
results suggest that caspase-8 inhibitors could be used in 
the prevention of SIRS. 
results
caspase-8 regulates human monocyte activation
To replicate the environment of SIRS in vitro, 
we treated the human monocytic cell line THP-1 with 
lipopolysaccharide (LPS); a PAMP that induces monocyte 
activation via TLR-4 signaling. The degree of activation 
was assessed by the expression of CD40, given it is 
upregulated in inflammatory monocytes and commonly 
used as a biomarker for SIRS [28]. In the presence 
of 1µg/ml LPS, we observed a moderate increase in 
caspase-8 activity at 6 and 24 hours post-treatment 
(Figure 1a). To test whether the LPS-induced increase of 
caspase-8 activity was associated to apoptotic cell death, 
we assessed the levels of cleaved Poly (ADP-ribose) 
polymerase (PARP-1), a known marker of apoptotic 
cell death. As seen in Figure 1b, LPS treatment failed 
to lead to increased cleaved PARP, demonstrating that 
the increase in caspase-8 activity was not due to an 
increase in apoptotic cell death. In order to test whether 
the observed increase in caspase-8 activity was required 
for monocyte activation, we pretreated THP-1 cells with 
the specific caspase-8 inhibitor IETD-fmk for 30 minutes 
prior to LPS challenge. We found that a 70% inhibition 
in caspase-8 activity was able to partially reverse the 
LPS-induced activation (Figure 1c-1e). Based on these 
results, we proceeded to assess the role of caspase-8 in a 
more physiological model consisting of human primary 
monocytes purified from peripheral blood. Like THP-1 
cells, primary monocytes experienced a moderate increase 
in caspase-8 activity in the presence of LPS (Figure 1e). 
Furthermore, a 70% decrease in caspase-8 activity was 
sufficient to partially decrease LPS-mediated activation 
(Figure 1f-1h). Together, these data suggest that caspase-8 
is involved in the activation of monocytes, and that the 
inhibition of its activity can be used to modulate the 
intensity of this activation. 
caspase-8 inhibition induces necroptosis of 
activated monocytes
We noticed that the combination of LPS and IETD-
fmk under the conditions stated above triggered high 
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levels of necrotic cell death in LPS-treated primary human 
monocytes (Figure 2a); an effect that we had not seen 
in THP-1 cells (data not shown). In order to determine 
which cell death pathway was involved, we measured the 
percentage of apoptotic and necrotic cells at shorter time-
points (Figure 2b). We found that there was no apoptosis 
prior to the induction of necrosis, meaning that the 
increase in necrotic cell death at 48 hours was not due to 
secondary necrosis. However, when we treated monocytes 
with the necroptosis inhibitor necrostatin-1 (Nec-1) for 15 
minutes prior to LPS challenge, this was found to reverse 
the cell death induced by caspase-8 inhibition, suggesting 
that necroptosis was taking place in activated monocytes 
treated with caspase-8 inhibitors (Figure 2c). 
caspase-8 inhibition decreases the levels of both 
pro- and anti-inflammatory cytokines associated 
to sIrs
Due to the necrotic nature of necroptotic cell 
death, we initially hypothesized that necroptosis of 
primary monocytes could cause the release of DAMPs, 
which could activate the remaining live monocytes and 
thus counteract the decrease in activation achieved by 
caspase 8 inhibition. Therefore, we firstly measured the 
Figure 1: caspase 8 regulates human monocyte activation. Figure a.-b. THP-1 cells were treated with 1 µg/ml LPS or 0.5 µg/ml 
STS. a) LETDase activity was measured and normalized against the number of cells at 6 and 24 hours post-treatment. LETDase activity 
is displayed on a discontinuous axis. b) Analysis of cleaved PARP levels by western blot at 3, 6 and 24 post-LPS-treatment. Three LPS 
concentrations were tested (1 µg/ml, 100 ng/ml and 10 ng/ml). Figure c.-e. THP-1 cells were treated with LPS (1 µg/ml) in the presence or 
absence of 20 µM of IETD-fmk for 48 hours. c) Histogram representation of the mean fluorescence channel for CD40. d) LETDase activity 
inhibition induced by IETD-fmk. e) Quantification of CD40 positive cells. Figure f. Human primary monocytes were treated with 1 µg/
ml LPS and LETDase activity was measured and normalized against the number of cells at 12 and 24 hours post-treatment. Figure g.-i. 
Human primary monocytes were treated with LPS (1 µg/ml) in the presence or absence of 20 µM of IETD-fmk for 48 hours. g) Histogram 
representation of the mean fluorescence channel for CD40. h) LETDase activity inhibition induced by IETD-fmk. i) Quantification of 
CD40 positive cells. Error bars represent standard deviation of the three experiments conducted. Statistical significance was assessed by 
Bonferroni test in e and h or Student’s t test in a, d, f and i. 
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mRNA expression levels of the main cytokines involved 
in SIRS: IL-1β, IL-10 and TNF-α, which were found to 
increase between 5 and 100-fold at 12 hours post-LPS 
treatment. However, despite the induction of necroptosis, 
we found that the pre-treatment with IETD-fmk did not 
increase the mRNA expression levels of any of the three 
cytokines, but rather caused a significant decrease in the 
mRNA expression of IL-10 and IL-1β (Figure 3a-3b). The 
expression levels of TNF-α were not altered by IETD-
fmk treatment (Figure 3c), however this may be due to 
the fact that TNF-α is induced during necroptosis. These 
findings strongly suggest that the removal by necroptosis 
Figure 2: caspase 8 inhibition induces necroptosis. Primary human monocytes were treated with LPS (1 µg/ml) in the presence or 
absence of 20 µM of IETD-fmk and/or of 25 µM Necrostatin-1. a. Dot plot showing viability in each condition. b. Percentage of apoptotic 
(Annexin V+/7-AAD-) cells and necrotic (7-AAD+) cells at 12 and 24 hours post-treatment. c. Variation of the percentage of necrotic cells 
in the presence or absence of Nec-1. d. Dot plot showing viable, necrotic and apoptotic cells in each condition. Error bars represent standard 
deviation of the three experiments conducted. Statistical significance was assessed by Bonferroni test.
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of the excess of monocytes that proliferate during sepsis 
would occur without further exacerbating the innate 
immune response. However, the possibility remained 
that necroptotic monocytes might themselves have 
released cytokines that could initiate the SIRS cytokine 
cascade. Thus, we measured the concentration of SIRS-
related cytokines in the media of necroptotic and non-
necroptotic cell cultures and found that, in spite of the 
50% necrosis induced by caspase-8 inhibition, the levels 
of pro-inflammatory IL-1β decreased significantly when 
monocytes were pre-treated with IETD-fmk prior to LPS 
challenge (Figure 3a). Of note, the addition of Nec-1 was 
found to induce a small, non-significant decrease in the 
concentration of IL-1β. With regards to the levels of anti-
inflammatory IL-10, we found a significant reduction 
under caspase-8 inhibition which was maintained in 
the presence of Nec-1. Given that the levels of both IL-
10 and IL-1β decrease under IETD-fmk treatment, we 
hypothesize that, unlike most conventional treatments, 
caspase-8 inhibition is able to counteract both phases of 
SIRS; pro- and anti-inflammatory. This would prevent the 
onset of the immunosuppressive stage and thus could be 
used as a potential clinical target in the treatment of SIRS.
The effects of caspase-8 inhibition in humans can 
only be replicated in mice by using broad caspase 
inhibitors
In order to extrapolate our results from human 
monocytes to a SIRS murine model, we firstly decided to 
confirm whether caspase-8 also played a role in murine 
monocyte activation. For this purpose, bone marrow 
monocytes were isolated from mice lacking caspase-8 
in the myeloid cell line (Caspase-8f/f LysMCre+/-). These 
mice, which were generated using flox-Cre technology, 
have been previously documented in studies on microglial 
and myeloid cells [29-34]. Monocytes were purified from 
the bone marrow by negative selection, as the isolated 
monocytes have been previously shown to be equivalent 
to blood monocytes [35]. The monocytes from these 
mice were then treated with LPS for 24 hours, after 
which the levels of monocyte activation and necroptosis 
were compared to those from LPS-treated wild-type 
Figure 3: Caspase 8 inhibition decreases the production and release of SIRS-related cytokines, but not necroptosis 
related cytokines. Primary human monocytes were treated with LPS (1 µg/ml) in the presence or absence of 20 µM of IETD-fmk and/
or 25 µM of Nec-1 for 12 and 36 hours. a. mRNA expression levels for IL-10. b. mRNA expression levels for IL-1β. c. mRNA expression 
levels for TNF-α. d. IL-1β concentration in the supernatant. e. IL-10 concentration in the supernatant. Error bars represent standard deviation 
of the three experiments conducted. Statistical significance was assessed by Bonferroni test. IETD = IETD-fmk.
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Figure 4: caspase-8 alone does not regulate murine monocyte activation. Figure a.-d. Primary monocytes from wild-type and 
knock-out mice were plated either alone or in the presence of 1 µg/mL LPS and/or 25 µM Necrostatin-1 for 24 hours. a) Percentage of 
activated (CD80 positive) monocytes. b) Percentage of necrotic (7-AAD positive) cells. c) Percentage of cleaved caspase 8 expression by 
flow cytometry. d) Differences in LETDase activity between wild-type and knock-out monocytes. Figure e.-h. Primary monocytes from 
wild-type mice were plated either alone or in the presence of 1 µg/mL LPS in the presence or absence of 20 µM IETD-fmk and/or 25 µM 
Necrostatin-1 for 24 hours e) LETDase activity inhibition induced by IETD-fmk. f) Percentage of activated (CD80 positive) monocytes g) 
Percentage of necrotic (7-AAD positive) cells. h) LETDase activity normalized against the number of cells . Error bars represent standard 
deviation of the three experiments conducted. Statistical significance was assessed by Bonferroni test in a, b, d, f and g and Student’s t test 
in c, e and h. 
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mice. Surprisingly, we were unable to find necroptosis 
or a decrease in monocyte activation in the cells of the 
knock-out mice treated with LPS (Figure 4a-4b), despite 
confirming a 40% decrease in cleaved caspase-8 by 
FACS (Figure 4c). We then measured caspase-8 activity 
in purified monocytes and found no difference between 
wild-type and knock-out mice, even in the presence of 
LPS. Based on these data, we conclude that the caspase-8 
gene is not efficiently deleted in bone-marrow-derived 
monocytes from Caspase-8f/f LysMCre+/- mice. 
Since the deletion of the caspase-8 gene in the 
mouse did not seem to replicate the effects of the chemical 
inhibition of caspase-8 achieved in humans, we decided to 
assess the effect of IETD-fmk on monocyte activation and 
necroptosis. Strikingly, despite achieving a 90% decrease 
in caspase-8 activity (Figure 4e), the chemical inhibition 
of caspase-8 neither resulted in necroptosis nor a decrease 
in the activation of LPS-treated murine monocytes (Figure 
4f-4g). Furthermore, when we quantified the changes in 
caspase-8 activity induced by LPS, we found a decrease 
rather than the increase expected based on the results 
in human monocytes (Figure 4h). Given this, it appears 
that there may be another factor which compensates for 
the lack of caspase-8 activity during murine monocyte 
activation.
It has been reported that some caspases exist only 
in certain species. For example, humans, but not mice, 
encode caspase-10 [36]. It was worth investigating 
whether murine monocyte activation may involve the 
activity of other caspases. Therefore, we assessed the 
effects of other caspase inhibitors on activation and 
necroptosis. We found that neither the specific caspase-9 
inhibitor, LEHD-fmk, nor the specific caspase-3 inhibitor, 
DEVD-fmk, had any effect on activation or cell death 
when added 30 minutes prior to LPS challenge (Figure 
5a-5b). However, when we pre-treated monocytes with the 
pan-caspase inhibitor z-VAD-fmk 30 minutes before LPS 
challenge, we fully reproduced the effects seen in human 
monocytes in terms of both activation and cell death 
(Figure 5c-5d). In fact, the co-treatment of monocytes with 
Figure 5: The pan-caspase inhibitor z-VAD-fmk reproduces the effects of caspase 8 inhibition in humans. Murine bone-
marrow monocytes were plated either alone or in the presence of 1 µg/mL of LPS and/or 20 µM of DEVD-fmk, LEHD-fmk or z-VAD-fmk 
and/or 25 µM Nec-1. a. Percentage of activated cells (CD80 positive) in the presence of DEVD-fmk and LEHD-fmk. b. Percentage of 
necrotic cells (7-AAD positive) in the presence of DEVD-fmk and LEHD-fmk. c. Percentage of necrotic cells in the presence of z-VAD-
fmk. d. Percentage of activated cells in the presence of z-VAD-fmk. Error bars represent standard deviation of the three experiments 
conducted. Statistical significance was assessed by Bonferroni test. 
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LPS and z-VAD-fmk reduced LPS-mediated activation 
by 20%, as well as inducing almost 60% necroptotic cell 
death, suggesting that other caspases may be involved in 
murine monocyte activation. Furthermore, given that, in 
both in humans and mice, a decrease in activation was 
never observed in the absence of necroptosis and vice 
versa, we hypothesize that necroptosis and a decrease in 
activation are linked phenotypes. 
dIscussIon
Monocytes have been described to play an essential 
role in the development of SIRS, since they are capable 
of modulating the innate immune response [8, 37]. In 
line with these facts, we hypothesize that the inhibition 
of monocyte activation could potentially ameliorate the 
innate immune response and thus diminish cytokine 
release [15, 16], as well as depleting the excess of over-
activated monocytes by necroptosis. We focused on 
caspase-8 as a potential regulator of monocyte activation, 
given its reported role in the activation and differentiation 
of innate immune cells [21, 38, 39]. We found that the 
induction of human monocyte activation with LPS 
induced a moderate increase in caspase-8 activity and 
that caspase-8 inhibition partially decreased LPS-induced 
activation, suggesting that caspase-8 regulates human 
monocyte activation. Interestingly, however, we noticed 
that the percentage of dead cells increased when caspase-8 
was inhibited in human primary monocytes, but not 
THP-1 cells, activated with LPS. The death induced by 
the combination of LPS and IETD-fmk was exclusively 
necrotic, a feature which had already been described in 
monocytic cells under caspase inhibition [18]. Given 
that caspase-8 has been shown to inhibit necroptosis via 
RIPK1 cleavage [17, 24], we hypothesized that, under 
caspase-8 inhibition, RIPK1 would remain active and thus 
be able to induce necroptosis via association with RIPK3 
and consequent MLKL activation. Under these conditions, 
targeting the kinase domain of RIPK1 with necrostatin-1 
inhibits the interaction between RIPK1 and RIPK3 [40]. 
We found that necrostatin-1 prevented the death induced 
by the combination of LPS and IETD-fmk; confirming 
the occurrence of necroptosis. The absence of necroptosis 
in THP-1 cells could relate to recent observations that 
several cell lines have been shown to have alterations in 
the necroptosis pathway [25]. 
Given its pro-inflammatory nature, caused by the 
release of DAMPs, it was possible that necroptosis might 
counter the effects of caspase-8 inhibition [27]. This 
therefore might limit the efficacy of caspase-8 inhibition 
as a viable treatment for SIRS. Indeed a previous study, 
using necrostatin-1 treated or RIPK3-/- mice has linked 
widespread necroptosis to the development of SIRS [41]. 
We hypothesized, however, that the anti-inflammatory 
effects of caspase-8 inhibition along with the specific 
depletion of activating monocytes by necroptosis would 
overcome the inflammatory effects of the released 
DAMPs. If this were the case, then the treatment of 
patients early with caspase-8 inhibitors would both 
decrease monocyte activation and lead to necroptosis of 
activating monocytes; cutting SIRS at the source. This 
would limit the resultant downstream symptoms including 
lymphocyte apoptosis and immunosuppression [42], which 
are not counteracted by other treatments. In support of this 
hypothesis, we detected lower levels of CD40 expression 
in the surviving monocytes of cultures where necroptosis 
had been induced with LPS and caspase-8 inhibitors. 
Furthermore, we found that, despite necroptosis, caspase-8 
inhibition was sufficient to decrease the expression and 
release of IL-1β. Together, this suggests that caspase-8 
inhibitors can control the inflammatory phase of SIRS. 
This data is in line with previous work which has shown 
that depletion of microglia by necroptosis can rescue 
the neuronal loss induced by activated microglia [43]. 
In addition, it has been demonstrated that L929 cells, a 
mouse fibrosarcoma cell line, subjected to TNF-induced 
necroptosis failed to induce pro-inflammatory cytokine 
production in macrophages [27]. A possible explanation 
for this is that, given active caspase-8 has been shown 
to be an important mediator of the release of DAMPs 
such as calreticulin [44], necroptosis under conditions of 
caspase-8 inhibition may be less inflammatory [27]. 
Given that active monocytes are also involved in the 
production of anti-inflammatory cytokines [6], we next 
wondered whether caspase-8 inhibition could control the 
anti-inflammatory phase of SIRS. We found that caspase-8 
inhibition was sufficient to decrease the expression and 
release of the anti-inflammatory cytokine IL-10, which is 
involved in the immunosuppressive stage of SIRS. Thus, 
we hypothesize here that IETD-fmk treatment could a) 
counteract the initial pro-inflammatory state of SIRS, by 
decreasing the release of IL-1β and depleting the excess of 
monocytes; and b) prevent the immunosuppressive state 
by inhibiting the production of IL-10 in the remaining live 
monocytes. 
Furthermore, it may also be that necroptosis itself 
has positive roles beyond the depletion of activated 
monocytes. The infusion of necrotic splenocytes 
prior to a sepsis challenge has been linked to reduced 
lymphocyte impairment and apoptosis, thus increasing 
survival via preventing the immunosuppressive stage of 
the syndrome [45]. Therefore, the presence of necrotic 
monocytes due to caspase-8 inhibition might also serve to 
stimulate the adaptive immune system and counteract the 
immunosuppressive stage.
It is interesting to note that caspase-8 has been 
involved in both priming and assembly of the NLRP3 
inflammasome [46, 47]. Although our study was not 
designed to study the role of caspase-8 in inflammasome 
activation, our data may shed light into this issue. It should 
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Figure 6: Mechanism of action of caspase-8 inhibitors in human monocytes. Scheme illustrating potential mechanisms by 
which caspase-8 might modulate the activation of monocytes (a) and how caspase-8 inhibition may selectively kill activated monocytes 
under conditions of SIRS (b). a. TLR activation in monocytes by LPS and other PAMPs and DAMPs (1) leads to priming of the monocytes; 
a process mediated by NF-kB activation (2, 3) and its nuclear translocation (4), to trigger transcription of target genes (e.g. IL-1β, IL-10 
and NLRP3) (5). Priming of monocytes results in the synthesis of the components of the NLRP3 inflammasome (6), whose assembly 
eventually leads to caspase-1 activation (7), cleavage of pro-IL1β to IL-1β and subsequent IL-1β release (8). IL1β is a major interleukin 
involved in innate immune responses. The ripoptosome, a molecular platform containing RIPK1, FADD, caspase-8 and cFLIP, forms in 
response to TLR activation in monocytes and possibly modulates the priming response, including NLRP3 activation. b. Effect of caspase-8 
inhibition on activated monocytes. Caspase-8 activity associated to the ripoptosome prevents necroptosis by selective cleavage of RIPK1. 
Consequently, selective inhibition of caspase-8 by IETD-fmk (9) results in RIPK1 activation and subsequent formation of the necrosome 
(10 and 11), thus leading to MLKL activation (12) and the induction of necroptosis. Loss of ripoptosome assembly may result in reduced 
priming by the mechanism shown above, thus leading to significantly lower expression of pro-IL1β and IL-10, and reduced NLRP3 
activation. Overall, caspase-8 inhibition leads to selective death of activated monocytes without exacerbating release of potential DAMPS. 
Red lines denote processes supported by our experimental data while black lines denote processes well-established in the literature.
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be highlighted that monocytes exhibit a distinctive one-
step pathway of inflammasome activation that can induce 
robust IL-1β release in response to TLR4 stimulation alone 
without the need for a secondary signal [48]. Our data 
shows that, regardless of necroptosis, caspase-8 inhibition 
strongly reduced the TLR4-induced mRNA expression 
(priming/activation) and release of IL-1β, supporting 
the hypothesis that caspase-8 regulates both processes 
[49-51]. Further work would be required to ascertain 
whether caspase-8 plays an inflammasome-dependent or 
independent role in IL-1β processing. 
Figure 6 illustrates a proposed mechanism based 
on our observations alongside well-established concepts 
in the literature. In human primary monocytes, the 
activation of TLR receptors leads to the expression of 
NF-kB-responsive genes such as IL-1β and IL-10. Our 
data suggests that the activation of caspase-8 alongside 
ripoptosome assembly takes place in response to TLR4 
activation. Furthermore, it highlights the possibility 
that caspase-8 might have a role in the priming and 
activation of monocytes. The data shown here contributes 
to a growing body of literature about the importance of 
caspase-8 in the pro-inflammatory activation of microglia 
[21, 22], macrophages [52] and now monocytes. We 
propose that under caspase-8 inhibition, two events 
take place: i) necroptotic death of active monocytes, 
ii) a significant reduction in the release of interleukins 
involved in SIRS like IL-1β and IL-10. Furthermore, 
as stated above, given the essential role of the NLRP3 
inflammasome in pro-IL1β processing and subsequent 
release, we anticipate an important role of caspase-8 in 
NLRP3 assembly within activated monocytes. 
When trying to apply our model to murine models 
of SIRS, our results showed that caspase-8 may not be 
the only enzyme involved in murine monocyte activation 
and necroptosis. In contrast to humans, where the 
specific inhibition of caspase-8 was sufficient to decrease 
monocyte activation and induce necroptosis, mouse 
monocytes required the use of a broad caspase inhibitor 
to induce a similar phenotype. Interestingly, the effects of 
pan caspase inhibitors have already been tested in mouse 
models of SIRS. Hotchkiss et al. (2000) demonstrated that 
the intraperitoneal injection of the pan-caspase inhibitor 
q-VD-OPh was able to increase survival of mice under 
conditions of septic shock (cecal ligation and puncture) 
as well as decreasing the levels of pro-inflammatory 
cytokines [12]. Furthermore, Weber et al. (2009) showed 
that the use of the broad caspase inhibitor VX-166 in mice 
also has positive effects in two complementary models of 
sepsis - endotoxin shock, and cecal ligation and puncture 
[53]. Like Hotchkiss et al., they also observed decreased 
circulating levels of pro-inflammatory cytokines in VX-
166 treated animals, thus supporting our observations. 
Although both studies attributed these effects to the 
prevention of lymphocyte apoptosis, it should be 
highlighted that lymphocyte apoptosis during SIRS is 
caused by monocyte over-activation [12, 53]. Thus, given 
our results show that treatment of murine monocytes with 
a pan-caspase inhibitor induces monocyte necroptosis and 
a decrease in monocyte activation, we hypothesize that this 
may be the cause of the observed decreased lymphocyte 
apoptosis and increased survival rate. Furthermore, given 
we found that the inhibition of a single protein, caspase-8, 
is able to reproduce the same effects in human monocytes, 
we hypothesize that the treatment of SIRS with caspase-8 
inhibitors may provide positive results. Furthermore, 
the use of caspase-8 inhibitors in place of pan-caspase 
inhibitors may also decrease the possible side effects 
derived from inhibiting all caspases.
MAterIAls And Methods
General chemical material
LPS from Escherichia coli 0111:B4 (Cat. No. 
L5293), IETD-fmk, LEHD-fmk and necrostatin-1 were 
purchased from Sigma-Aldrich (St Louis, MO, USA). 
Z-VAD-fmk was purchased from Promega (Madison, 
USA). DEVD-fmk was obtained from Becton Dickinson 
Bioscience (San Jose, CA, USA). PBS, RPMI-1640, FBS, 
trypsin and antibiotics were purchased from GIBCO 
(InvitrogenTM, Paisely, UK). AB serum, L-glutamine, 
β-mercaptoethanol, PFA, methanol and bovine albumin 
(BSA) were purchased from Sigma-Aldrich (St Louis, 
MO, USA). MACS running buffer, columns and MACS 
separators were from Miltenyi Biotec S.L. (Bergisch 
Gladbach, Germany). 
cell culture and monocyte isolation
Human monocytes were isolated from buffy-coats 
obtained from healthy donors in accordance with the 
Declaration of Helsinki. All procedures were performed 
based on the regulations established by the Ethical 
Committee of Virgen del Rocío Hospital (Seville, Spain). 
Monocytes were then isolated from the mononucleate 
cell fraction by immunomagnetic separation using CD14 
microbeads (Miltenyi Biotec S.L. Bergisch Gladbach, 
Germany), following manufacturer’s instructions, and 
grown in RPMI-1640 supplemented with 10% AB 
serum. THP-1 cells (ATCC® TIB202™) were obtained 
from Sigma-Aldrich (88081201) and cultured in RPMI-
1640 containing 10% FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate and 0.05 mM β-mercaptoethanol. All 
experimentation was carried out at Cancer Centrum 
Karolinska (CCK), Stockholm (Sweden), in accordance 
with national and European regulations. 
Animal experimentation was carried out at the 
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University of Seville, in accordance with the regulations 
established by in accordance with the Guidelines of 
the European Union Council (86/609/EU), following 
Spanish regulations (BOE 34/11370-421, 2013) for the 
use of laboratory animals and approved by the Scientific 
Committee of the University of Seville. Animals were kept 
in specific pathogen-free conditions and had free access 
to food and water. Caspase-8f/f C57BL/6 mice (with the 
CASP8allele floxed at exon 3) were generously provided 
by Prof. Steven M. Hedrick (University of California, 
San Diego) [54] (Figure 1a). C57BL/6 mice containing 
a Cre recombinase under the control of LysM promoter 
and enhancer elements, which allow its expression in the 
myeloid cell linage, including microglia, were obtained 
from Jackson Laboratories (strain name B6.129P2-
Lyz2tm1(cre)Ifo/J). A cross was set up between both 
strains and the offspring were Casp8f/+.CreLysM+/-. These 
offspring were crossed with Casp8f/f to generate Casp8f/f.
CreLysM+/- (myeloidCasp8KO mice) and Casp8f/f. 
CreLysM-/- (WT mice). In order to make the breeding 
process more efficient, we crossed Casp8f/f. CreLysM+/- 
with Casp8f/f mice to generate a 50 % Casp8f/f.CreLysM+/- 
and 50 % Casp8f/f.CreLysM-/-. Homozygous floxed Casp8f/f 
mice were born at the predicted Mendelian ratio and were 
indistinguishable from littermates. Wild type, single, and 
double floxed targeted Casp8-/- alleles were genotyped by 
PCR. For monocyte isolation, 6-8 week-old mice were 
sacrificed by cervical dislocation and the bone marrow was 
harvested by standard techniques. Monocytes were then 
purified by negative selection using the BM Monocyte 
Isolation Kit (Miltenyi Biotec S.L., Bergisch Gladbach, 
Germany) [30], following manufacturer’s instructions, 
and cultured in RPMI-1640 supplemented with 10% FBS. 
To induce monocyte activation, 2x105 primary human 
and murine monocytes were plated in flat-bottom 96-well 
plates. THP-1 cells were plated in flat-bottom 12-well 
plates at 2x105 cells/well. All cells were treated with 1 µg/
ml LPS and/or 20 µM of caspase inhibitor for 30 minutes 
before LPS, and/or 25 µM necrostatin-1 for 15 minutes 
before LPS.
caspase 8 activity assay
Changes in caspase activity in were measured using 
a luciferase-based assay from Promega (Madison, USA) 
known as Caspase-Glo (G8200 for caspase-8). Equal 
volumes of cells and kit component were mixed onto a 96-
well plate (Costar® White plates, Sigma-Aldrich, St Louis, 
MO, USA) and incubated for 1 h at room temperature. 
The plate was analyzed using a luminometer (Promega, 
Madison, USA) according to manufacturer’s specifications 
and the value obtained normalized with the number of 
cells at harvest.
Flow cytometry
To assess activation levels, cells were detached, 
washed and resuspended in PBS, and 1 x 105 cells in 
100 µl PBS were stained with antibodies using a 4-color 
combination as specified in Tables 1 and 2. Samples 
were incubated for 15 min in the dark and the excess of 
antibodies was washed with PBS at 300 g for 10 min. 
Prior to acquisition, 5 µl of 7-aminoactinomycin D (7-
AAD) (Becton Dickinson Bioscience. San Jose, CA, 
USA) was added. A total of 50000 events were acquired 
in a FACSCantoII (Becton Dickinson Bioscience, San 
Jose, CA, USA) and the percentage of activated cells 
in the live cell population was gated using the Flow Jo 
software program (FlowJo LLC, OR, USA). For cell 
table 1: Antibodies used in murine monocyte activation studies
Antibody Fluorochrome Isotype Volume used company
CD11b FITC Rat IgG2b 10 µl Miltenyi Biotec S.L. Bergisch Gladbach, Germany
CD45 VioBlue Rat IgG2bκ 10 µl Miltenyi Biotec S.L. Bergisch Gladbach, Germany
CD80 PE Hamster IgG2 10 µl Miltenyi Biotec S.L. Bergisch Gladbach, Germany
table 2: Antibodies for human monocyte activation studies
Antibody Fluorochrome Isotype Volume used company
HLA-DR APC Mouse IgG1κ 5 µl Becton Dickinson Bioscience San Jose CA USA
CD45 FITC Mouse IgG1κ 10 µl Becton Dickinson Bioscience San Jose CA USA
CD40 PE Mouse IgG1 10 µl Beckman Coulter Company Marselle France
CD14 APC-H7 Mouse IgG2a κ 5 µl Becton Dickinson Bioscience San Jose CA USA
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death assays, the Annexin V PE/7-AAD Kit from BD 
Pharmingen was used. Cells were stained with 5 µl of 
Annexin V and 5 µl of 7-AAD in combination to quantify 
the percentages of apoptotic (Annexin V+/7-AAD-) and 
necrotic (AnnexinV+/7-AAD+) cells. For intracellular, 
cleaved caspase-8 staining, bone marrow monocytes were 
washed with PBS and fixed with PFA and permeabilized 
with 90% methanol. Cells were washed and blocked 
(0.5% BSA in PBS), and labeled with anti-cleaved Casp8 
antibody (Asp387) (Cell Signalling, Danvers, MA, USA) 
(D5B2) (1:800) and a secondary anti-rabbit fluorescein 
conjugated secondary antibody (Vector Laboratories, 
Burlingame, CA, USA). 
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated with the RNeasy Mini Kit 
(Qiagen, Venlo, Holland) according to manufacturer’s 
instructions. cDNA was synthesized from up to 1 μg of 
total RNA using the QuantiTect Reverse Transcription 
Kit (Qiagen, Venlo, Holland). The cDNA concentration 
was measured with a Nanodrop 1000 (Thermo Fischer 
Scientific, Nunc A/S, Kamstrupvej, Roskilde, Denmark) 
and 750 ng of cDNA was added to each qPCR reaction. 
The qPCR was performed using SensiMixPlus SYBR 
(Quantace, Bioline, Taunton, MA, USA) on a Mastercycler 
ep gradient S realplex2 (Eppendorf, Hamburg, Germany). 
All primer sets had similar Tm values and amplified short 
fragments, spanning an intron and recognizing all or most 
of the cDNA splicing variants described (Table 3). All 
primers were designed with the Universal ProbeFinder 
v2.44 software (Roche Applied Science; Roche Farma, 
S.A., Madrid, Spain) and verified by Oligo Analyzer 3.1 
(Integrated DNA Technologies, Coralville, IA, USA). The 
amplification program was 10 minutes at 95ºC followed 
by 45 cycles of 15 s at 95ºC, 30 s at 60ºC, 8 s at 72ºC, 
and a final extension step of 5 minutes at 72ºC. A melting 
curve from 50ºC to 95ºC in 30 minutes was used to verify 
specificity. Relative expression levels were calculated in 
triplicate using the comparative CT method with β-actin 
as a housekeeping gene.
Enzyme-linked immunosorbent assay
Cytokine concentration was quantified in cell culture 
supernatants using IL-1β (human) ELISA kit (Enzo Life 
Sciences Farmingdale, NY, USA) for the determination of 
IL-1β, and IL-10 (human) ELISA kit (Enzo Life Sciences, 
Farmingdale, NY, USA) for IL-10. All the experiments 
were performed following manufacturer’s procedures. 
Absorbance was read at 450 nm, in a Synergy HT plate 
reader (BioTek Winooski, VT, USA). 
statistical analysis
All data are presented as mean ± standard deviation/
range of either absolute values or percentages. Statistical 
analyses were performed using IBM SPSS Statistics 19 
software. Statistical significance was assessed by Student’s 
t-test or one-way ANOVA followed by the Bonferroni test. 
In all the tests, P values were P < 0.05 (*), P < 0.01 (**) 
and P < 0.001 (***). 
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